Trial Profile
Long-term efficacy study of anti-VEGF monotherapy with ranibizumab or bevacizumab in patients with retinal angiomatous proliferation : A retrospective case series study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Oct 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 13 Oct 2016 New trial record